RAF and MEK inhibitor therapy in adult patients with brain tumors: A case-based overview and practical management of adverse events

Karisa Schreck, Mallika P. Patel, Jan Wemmer, Stuart A. Grossman, Katherine B. Peters

Research output: Contribution to journalArticlepeer-review

Abstract

Targeted therapy has gained mainstream attention with notable successes against specific genetic mutations in many cancers. One particular mutation, the BRAFV600E mutation, is present in a small subset of gliomas in adults. Although clinical experience and trial data of RAF-targeted therapy in adults with glioma are lacking at this time, the poor prognosis of adult high-grade glioma has led neuro-oncology practitioners to consider the use of targeted therapy in these patients. In this manuscript, we describe the use of RAF and MEK inhibitors in adults with recurrent glioma. We discuss the utility of these agents, describe their toxicities, and give examples of management strategies. Given the significant toxicities of RAF and MEK inhibitors, along with the long potential duration of treatment, neuro-oncology providers should counsel patients carefully before initiating therapy and monitor them closely while undergoing treatment with RAF-targeted therapy.

Original languageEnglish (US)
Pages (from-to)369-375
Number of pages7
JournalNeuro-Oncology Practice
Volume7
Issue number4
DOIs
StatePublished - Aug 1 2020

Keywords

  • Adult
  • BRAF
  • Glioma
  • Management
  • MEK
  • RAF
  • Toxicity

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Fingerprint Dive into the research topics of 'RAF and MEK inhibitor therapy in adult patients with brain tumors: A case-based overview and practical management of adverse events'. Together they form a unique fingerprint.

Cite this